Literature DB >> 31410752

The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective.

Palle Bekker Jeppesen1.   

Abstract

The ability to provide parenteral support represents a revolutionary change in medical therapy for patients with temporary and inadequate intestinal absorptive capacity or for patients with chronic intestinal failure due to digestive diseases. Nevertheless, due to the rarity of intestinal failure, a de facto policy of "discrimination by organ failure treatment" exists in many countries whereby this problem is under-recognized and under-treated. With the increasing recognition of the pathophysiological consequences of intestinal resection and the occurrence of new pro-adaptive treatments for patients suffering from short bowel syndrome, this review reflects on the history of developments in this area and discusses current practice and future directions of the field.

Entities:  

Keywords:  Adaptation; Glucagon-like peptide 1; Glucagon-like peptide 2; Growth hormone; Intestinal resection; Malabsorption; Parenteral support; Somatostatin

Mesh:

Year:  2019        PMID: 31410752     DOI: 10.1007/s10620-019-05779-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  99 in total

1.  Survey on legislation and funding of home artificial nutrition in different European countries.

Authors:  J M Moreno ; J Shaffer ; M Staun ; X Hebuterne ; F Bozzetti ; M Pertkiewicz ; P Thul ; A Van Gossum
Journal:  Clin Nutr       Date:  2001-04       Impact factor: 7.324

Review 2.  The enteric nervous system: a second brain.

Authors:  M D Gershon
Journal:  Hosp Pract (1995)       Date:  1999-07-15

Review 3.  A global perspective of home parenteral and enteral nutrition.

Authors:  L Howard
Journal:  Nutrition       Date:  2000 Jul-Aug       Impact factor: 4.008

4.  Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

Authors:  P B Jeppesen; B Hartmann; J Thulesen; J Graff; J Lohmann; B S Hansen; F Tofteng; S S Poulsen; J L Madsen; J J Holst; P B Mortensen
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

5.  Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study.

Authors:  J Szkudlarek; P B Jeppesen; P B Mortensen
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study.

Authors:  P B Jeppesen; J Szkudlarek; C E Høy; P B Mortensen
Journal:  Scand J Gastroenterol       Date:  2001-01       Impact factor: 2.423

7.  Quality of life in patients receiving home parenteral nutrition.

Authors:  P B Jeppesen; E Langholz; P B Mortensen
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

8.  Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.

Authors:  P B Jeppesen; B Hartmann; J Thulesen; B S Hansen; J J Holst; S S Poulsen; P B Mortensen
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

9.  Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure.

Authors:  P B Jeppesen; B Hartmann; B S Hansen; J Thulesen; J J Holst; P B Mortensen
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

10.  Intestinal failure defined by measurements of intestinal energy and wet weight absorption.

Authors:  P B Jeppesen; P B Mortensen
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

View more
  6 in total

1.  Control of Intestinal Epithelial Proliferation and Differentiation: The Microbiome, Enteroendocrine L Cells, Telocytes, Enteric Nerves, and GLP, Too.

Authors:  Jonathan D Kaunitz; Yasutada Akiba
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

2.  Short-Bowel Syndrome: Epidemiology, Hospitalization Trends, In-Hospital Mortality, and Healthcare Utilization.

Authors:  Mohamed Tausif Siddiqui; Wael Al-Yaman; Amandeep Singh; Donald F Kirby
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-12-17       Impact factor: 3.896

3.  Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.

Authors:  Ulrich-Frank Pape; Kishore R Iyer; Palle B Jeppesen; Marek Kunecki; Loris Pironi; Stéphane M Schneider; Douglas L Seidner; Hak-Myung Lee; John Caminis
Journal:  Therap Adv Gastroenterol       Date:  2020-04-20       Impact factor: 4.409

4.  Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency.

Authors:  Johannes Reiner; Peggy Berlin; Jakob Wobar; Holger Schäffler; Karen Bannert; Manuela Bastian; Brigitte Vollmar; Robert Jaster; Georg Lamprecht; Maria Witte
Journal:  Dig Dis Sci       Date:  2020-02-19       Impact factor: 3.199

5.  Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.

Authors:  Johanna Eliasson; Mark K Hvistendahl; Nanna Freund; Federico Bolognani; Christian Meyer; Palle B Jeppesen
Journal:  JPEN J Parenter Enteral Nutr       Date:  2022-03-28       Impact factor: 3.896

6.  Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.

Authors:  Johanna Eliasson; Mark K Hvistendahl; Nanna Freund; Federico Bolognani; Christian Meyer; Palle B Jeppesen
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-09-07       Impact factor: 3.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.